Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Investig Clin Urol ; 62(1): 39-46, 2021 01.
Article in English | MEDLINE | ID: mdl-33314806

ABSTRACT

PURPOSE: Nearly half of penile cancers are related to human papillomavirus (HPV) infection. Investigations of tumor- and HPV-specific T cell reactivity in regional lymph nodes (LNs) from patients with penile cancer are warranted. MATERIALS AND METHODS: In this study, single-cell suspensions from LNs and peripheral blood from 11 patients with penile cancer were stained with antibodies for lymphocyte markers and analyzed by fluorescence-activated cell sorting (FACS). DNA was extracted from the tumor tissue and HPV status was investigated by PCR. RESULTS: T-cell reactivity against autologous tumor-extract and against the HPV-vaccine Gardasil® was tested by flow-cytometric assay of specific cell-mediated immune response in activated whole blood (FASCIA). CD4+/CD8+ ratios were significantly lower in HPV positive LNs (p<0.05). Immune responses to tumor extract assessed by blast transformation and expansion in vitro, of either CD4+ or CD8+ T-cells, were found in 9 of 13 LNs (69%). 5 of 6 tested patients demonstrated T cell recognition of tumor-associated antigen(s). In HPV-positive patients, dose-dependent T cell responses against L1 (late) HPV proteins (Gardasil vaccine) were demonstrated. CONCLUSIONS: LN-derived T cells from patients with penile cancer recognize tumor antigen(s) and in HPV-positive cases, there is a response against L1 (late) HPV proteins, being constituents of the Gardasil vaccine.


Subject(s)
Antigens, Neoplasm/immunology , Lymph Nodes/immunology , Papillomaviridae/immunology , Penile Neoplasms/immunology , Penile Neoplasms/virology , Aged , Aged, 80 and over , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/immunology , Humans , Immunophenotyping , Lymphocyte Activation , Male , Middle Aged , Papillomaviridae/genetics , Viral Proteins/immunology
2.
BMC Urol ; 18(1): 86, 2018 Oct 05.
Article in English | MEDLINE | ID: mdl-30290760

ABSTRACT

BACKGROUND: The tumor draining lymph node concept was first described in penile cancer for staging. Immunohistochemistry and histopathology evaluations are routinely used in clinical practice to examine lymph nodes for metastasis. However, these methods are time-consuming with low diagnostic accuracy and micro-metastases might be missed. In this study, we aim to evaluate detection of metastatic cells in draining lymph nodes by flow cytometry. METHODS: To assess the sensitivity of micro-metastasis detection by FACS (Fluorescence-activated cell sorting), HeLa cells were titrated into Peripheral blood mononuclear cells (PBMCs) and expression of pan-cytokeratin AE1/AE3 was analyzed. Single cell suspensions were separately prepared from 10 regional lymph nodes obtained from 5 patients with invasive penile cancer undergoing radical surgery and lymph node dissection. Lymph node dereived cells were examined for cell surface expression of EpCAM, E-cadherin and intracellular expression of pan-cytokeratin AE1/AE3 by FACS. RESULTS: Ten lymph nodes from 5 penile cancer patients were investigated in a head-to-head comparison between FACS and pathology examination of sections. All metastatic lymph nodes verified by pathology examination were also identified by FACS. Two additional lymph nodes with micro-metastases were diagnosed by FACS only. CONCLUSIONS: FACS analyses of pan-cytokeratin AE1/AE3 stained single cells from tumor draining lymph nodes can be used to detect micro-metastases in patients with penile cancer patients.


Subject(s)
Flow Cytometry , Keratins/metabolism , Lymph Nodes/metabolism , Neoplasm Micrometastasis/diagnosis , Penile Neoplasms/pathology , Aged , Aged, 80 and over , Antigens, CD/metabolism , Biomarkers/metabolism , Cadherins/metabolism , Epithelial Cell Adhesion Molecule/metabolism , HeLa Cells , Humans , Leukocytes, Mononuclear/metabolism , Lymph Nodes/cytology , Lymph Nodes/pathology , Lymphatic Metastasis/diagnosis , Male , Sensitivity and Specificity
3.
Onco Targets Ther ; 10: 3453-3465, 2017.
Article in English | MEDLINE | ID: mdl-28761354

ABSTRACT

BACKGROUND: Adoptive T cell therapy has been proven to be a promising modality for the treatment of cancer patients in recent years. However, the increased expression of inhibitory receptors could negatively regulate the function and persistence of transferred T cells which mediates T cell anergy, exhaustion, and tumor regression. In this study, we investigated increased cytotoxic activity after the blockade of PD-1 for effective immunotherapy. METHODS: The cytotoxic function of expanded CD8+ CTLs and interactions with tumor cells investigated after blocking of PD-1. Ex vivo expanded CD8+ CTLs were co-cultured with mismatch repair (MMR) stable or deficient (high microsatellite instability [MSI-H]) EpCAM+ tumor cells. The levels of IFN-γ and GrB were detected by enzyme-linked immunosorbent spot assay. Flow cytometry and confocal microscopy were used to assess CD107a mobilization, cytosolic uptake, and cell migration. RESULTS: A dramatic increase in PD-1 expression on the surface of CD8+ CTLs during ex vivo expansion was observed. PD-1 level was downregulated by approximately 40% after incubation of the CD8+ CTLs with monoclonal antibody which enhanced the secretion of IFN-γ, GrB, and CD107a. Additionally, PD-1 blockade enhanced cell migration and cytosolic exchange between CD8+ CTLs and MMR deficient (MSI-H) EpCAM+PD-L1+ tumor cells. CONCLUSION: The blockade of PD-1 enhanced the cytotoxic efficacy of CD8+ CTLs toward MMR deficient tumor cells. In conclusion, we propose that blocking of PD-1 during the expansion of CD8+ CTLs may improve the clinical efficacy of cell-based adoptive immunotherapy.

4.
J Comput Assist Tomogr ; 40(3): 413-8, 2016.
Article in English | MEDLINE | ID: mdl-26953769

ABSTRACT

OBJECTIVE: The aim of the study was to investigate the utility of intravoxel incoherent motion (IVIM) diffusion-weighted magnetic resonance imaging (DWI) for differentiating nasopharyngeal carcinoma (NPC) from lymphoma. METHODS: Intravoxel incoherent motion-based parameters including the apparent diffusion coefficient (ADC), pure diffusion coefficient (D), pseudodiffusion coefficient (D*), perfusion fraction (f), and fD* (the product of D* and f) were retrospectively compared between 102 patients (82 with NPC, 20 with lymphoma) who received pretreatment IVIM DWI. RESULTS: Compared with lymphoma, NPC exhibited higher ADC, D, D*, fD* values (P < 0.001) and f value (P = 0.047). The optimal cutoff values (area under the curve, sensitivity, and specificity, respectively) for distinguishing the 2 tumors were as follows: ADC value of 0.761 × 10 mm/s (0.781, 93.90%, 55.00%); D, 0.66 × 10 mm/s (0.802, 54.88%, 100.00%); D*, 7.89 × 10 mm/s (0.898, 82.93%, 85.00%); f, 0.29 (0.644, 41.46%, 95.00%); and fD*, 1.99 × 10 mm/s (0.960, 85.37%, 100.00%). CONCLUSIONS: Nasopharyngeal carcinoma exhibits different IVIM-based imaging features from lymphoma. Intravoxel incoherent motion DWI is useful for differentiating lymphoma from NPC.


Subject(s)
Diffusion Magnetic Resonance Imaging , Image Enhancement , Image Interpretation, Computer-Assisted , Imaging, Three-Dimensional/methods , Lymphoma/diagnostic imaging , Nasopharyngeal Neoplasms/diagnostic imaging , Algorithms , Diagnosis, Differential , Humans , Motion , Reproducibility of Results , Sensitivity and Specificity , Tumor Burden
5.
Cancer Immunol Immunother ; 64(9): 1083-93, 2015 Sep.
Article in English | MEDLINE | ID: mdl-25990075

ABSTRACT

Although the development of multi-disciplinary management has improved the survival of colorectal cancer (CRC), the prognosis of metastatic CRC patients remains poor. Accumulating evidence has demonstrated that immunotherapy with cancer vaccines and adoptive T cell transfusions may improve outcomes as an adjuvant to current standard CRC treatment. In this phase I/II study, 71 CRC patients who underwent radical surgery (stage I-III, n = 46) or palliative surgery (stage IV with non-resectable synchronous metastases, n = 25) were included. In the first part of this study, sentinel lymph nodes (SLNs) were intraoperatively identified in 55 patients (46 with stage I-III CRC and 9 with stage IV CRC). SLN-T lymphocytes were expanded ex vivo for a median of 28.5 days (range 23-33 days). Thereafter, a median of 153 × 10(6) cells (range 20.7-639.0 × 10(6)) were transfused. No treatment-related toxicity was observed. In the second part of this study, the stage IV patients were routinely followed. The 24-month survival rate of the SLN-T lymphocyte group was significantly higher than that of the control group: 55.6 versus 17.5% (p = 0.02). The median overall survival of the SLN-T lymphocyte and control groups was 28 and 14 months, respectively. Our study showed that adjuvant SLN-T lymphocyte immunotherapy is feasible and safe for postoperative CRC patients. Additionally, this therapy may improve the long-term survival of metastatic CRC. Further investigation of the clinical efficacy and anti-tumor immunity is warranted.


Subject(s)
Colorectal Neoplasms/immunology , Colorectal Neoplasms/therapy , Immunotherapy, Adoptive/methods , Immunotherapy/methods , Lymph Nodes/pathology , T-Lymphocytes/immunology , T-Lymphocytes/transplantation , Adjuvants, Immunologic , Aged , Colorectal Neoplasms/pathology , Female , Humans , Male , Middle Aged , Prognosis , T-Lymphocytes/pathology
6.
Proc Natl Acad Sci U S A ; 105(14): 5609-13, 2008 Apr 08.
Article in English | MEDLINE | ID: mdl-18385373

ABSTRACT

The neuropeptide galanin R1 receptor (GalR1) was tagged at its C terminus with EGFP (GalR1-EGFP) to study receptor localization and trafficking. In PC12 and HEK293 cells, functional GalR1-EGFP was expressed on the plasma membrane and internalized into cytoplasmic vesicles after galanin stimulation. The internalization was blocked by 0.4 M sucrose and by silencing of clathrin with siRNA methodology. Internalized GalR1-EGFP and LysoTracker, a lysosomal marker, overlapped in intracellular vesicles after prolonged galanin stimulation. This colocalization was strongly reduced after site-directed mutagenesis of the motif YXXØ on the C terminus of GalR1 (where Ø is a bulky hydrophobic residue and X any amino acid). Taken together, these data suggest that GalR1 is internalized via the clathrin-dependent, endocytic pathway and then, to a large extent, delivered to lysosomes for degradation through the lysosome-targeting signal YXXØ.


Subject(s)
Endocytosis , Lysosomes/metabolism , Receptor, Galanin, Type 1/metabolism , Amino Acid Motifs/physiology , Cell Line , Clathrin , Cytoplasm/metabolism , Endosomes/metabolism , Galanin/pharmacology , Green Fluorescent Proteins , Humans , Protein Transport , Sucrose
7.
Biochem Pharmacol ; 70(4): 598-605, 2005 Aug 15.
Article in English | MEDLINE | ID: mdl-15979585

ABSTRACT

Adenosine and adenosine analogues have been reported to act as agonists or partial agonists at the growth hormone secretagogue receptor 1a (GHSR1a). We have re-examined this question. A concentration-dependent increase in intracellular calcium concentration ([Ca(2+)](i)) was observed in GHSR1a transfected HEK 293-EBNA cells stimulated with adenosine (EC50: 0.2 microM) or 2-chloroadenosine (EC50: 1.1 microM) but also in untransfected HEK 293-EBNA cells stimulated with 2-chloroadenosine (EC50: 0.67 microM) or 5'-N-ethylcarboxamidoadenosine (NECA) (EC50: 0.045 microM). These findings support endogenous expression of adenosine receptors, presumably A(2B) receptors in HEK 293-EBNA cells. In GHSR1a transfected CHO cells, lacking adenosine receptors, the GHSR1a agonist hGhrelin (EC50: 2.4 nM) increased [Ca(2+)](i), but no effects of adenosine, 2-chloroadenosine or NECA were detected. An inverse agonist of GHSR1a, [d-Arg-1, d-Phe-5, d-Trp-7, 9, Leu-11] substance P, reduced hGhrelin effects but adenosine, 2-chloroadenosine or 1,3-dipropyl-8-cyclopentylxanthine (DPCPX) did not. NECA increased the [Ca(2+)](i) in co-transfected (GHSR1a and A(2B) receptor) CHO cells (EC50: 0.053 microM), but no additive or synergistic effects on [Ca(2+)](i) or cAMP formation were observed after stimulation with NECA in the absence or in the presence of hGhrelin. In binding studies on GHSR1a transfected CHO cell membranes, [(125)I]-hGhrelin binding could be displaced by the GHSR1a agonist MK-0677 (IC50: 0.34 nM), hGhrelin (IC50: 1.5 nM), and the substance P analogue (IC50: 0.64 microM) but not by adenosine or 2-chloroadenosine. We conclude that adenosine and analogues do not act as agonists or partial agonists at the GHSR1a and that cross-talk between the GHSR1a and A(2B) receptors is limited.


Subject(s)
Adenosine/pharmacology , Receptors, G-Protein-Coupled/agonists , Adenosine/analogs & derivatives , Adenosine/metabolism , Animals , CHO Cells , Calcium/metabolism , Cell Line , Cricetinae , Cyclic AMP/metabolism , Ghrelin , Glutathione/metabolism , Humans , Peptide Hormones/metabolism , Radioligand Assay , Receptors, Ghrelin , Signal Transduction
8.
Neuropeptides ; 39(3): 173-8, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15885774

ABSTRACT

In the present experiments trafficking of the galanin R1-(GALR1) and, in particular, the galanin R2 receptor (GALR2) was studied after fusion with enhanced green fluorescent protein (GALR1-EGFP and GALR2-EGFP) and transfection into PC12 cells. Both fusion proteins were predominantly localized on the plasma membrane and internalized in a dose dependent manner after incubation with galanin. Preincubation with M35 or M40 did not prevent galanin-induced internalization of GALR1-EGFP or GALR2-EGFP. However, AR-M1896, a selective GALR2 agonist, caused GALR2, but not GALR1 internalization. Hyperosmotic sucrose inhibited internalization of GALR2-EGFP. After co-incubation with galanin, GALR2-EGFP was co-localized with internalized Texas Red transferrin, a marker of the clathrin endocytic pathway. Experiments with protein synthesis inhibition and Texas Red transferrin suggest that GALR2 is constitutively internalized. Studies in progress will show if this is the case also for GALR1.


Subject(s)
Endocytosis/physiology , Receptor, Galanin, Type 1/genetics , Receptor, Galanin, Type 1/metabolism , Receptor, Galanin, Type 2/genetics , Receptor, Galanin, Type 2/metabolism , Animals , Bradykinin/analogs & derivatives , Bradykinin/pharmacology , Calcium Signaling/physiology , Fluorescent Dyes/pharmacology , Galanin/pharmacology , Green Fluorescent Proteins/genetics , Ligands , Neurons/metabolism , PC12 Cells , Peptide Fragments/pharmacology , Protein Transport/physiology , Rats , Receptor, Galanin, Type 1/agonists , Receptor, Galanin, Type 2/agonists , Transfection , Xanthenes/pharmacology
9.
Proc Natl Acad Sci U S A ; 101(42): 15207-12, 2004 Oct 19.
Article in English | MEDLINE | ID: mdl-15471987

ABSTRACT

Trafficking of the galanin R2 receptor (GALR2) fused with enhanced GFP (EGFP) was studied by using confocal fluorescence microscopy. The fusion protein was predominantly localized on the plasma membrane with some intracellular fluorescent structures (vesicles), mainly in the perinuclear region. Incubation with galanin resulted in a concentration-dependent increase in intracellular Ca2+ concentration levels, suggesting that the GALR2-EGFP conjugate is functional. After blocking endocytosis with methyl-beta-cyclodextrin GALR2-EGFP expression was increased on the surface and decreased in the cytoplasm. Blocking endocytic recycling with monensin caused an increase of intracellular GALR2-EGFP accumulation and a decrease of fluorescence on the plasma membrane. GALR2-EGFP on the plasma membrane was internalized within 5-10 min after treatment with galanin or AR-M1896, a selective GALR2 agonist, with a dramatic reduction in plasma membrane localization and appearance in intracellular vesicles. Neither M35 nor M40, two galanin analogues with putative antagonistic action, prevented GALR2 agonist-induced internalization of GALR2-EGFP, suggesting that they are not antagonists at this receptor under the present circumstances. Galanin stimulation at low temperature caused GALR2-EGFP aggregation and clustering on the surface but no translocation to cytoplasm. After coincubation with galanin the GALR2-EGFP was colocalized with internalized Texas red-transferrin, a marker of the clathrin endocytic pathway. Hyperosmotic sucrose inhibited internalization of GALR2-EGFP. Taken together these findings indicate that GALR2 undergoes constitutive endocytosis and recycling and that both ligand-independent and ligand-dependent internalization use the clathrin-dependent endocytic recycling pathway.


Subject(s)
Receptor, Galanin, Type 2/metabolism , Animals , Base Sequence , DNA/genetics , Endocytosis/drug effects , Galanin/analogs & derivatives , Galanin/metabolism , Galanin/pharmacology , Ligands , PC12 Cells , Rats , Receptor, Galanin, Type 2/genetics , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Spectrometry, Fluorescence , Subcellular Fractions/metabolism , Transfection
SELECTION OF CITATIONS
SEARCH DETAIL
...